AR104863A1 - Derivados imidazol - Google Patents

Derivados imidazol

Info

Publication number
AR104863A1
AR104863A1 ARP160101615A ARP160101615A AR104863A1 AR 104863 A1 AR104863 A1 AR 104863A1 AR P160101615 A ARP160101615 A AR P160101615A AR P160101615 A ARP160101615 A AR P160101615A AR 104863 A1 AR104863 A1 AR 104863A1
Authority
AR
Argentina
Prior art keywords
methyl
cyclopropyl
ch2oh
ethyl
hydrogen
Prior art date
Application number
ARP160101615A
Other languages
English (en)
Inventor
Wichmann Juergen
Hoener Marius
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR104863A1 publication Critical patent/AR104863A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Abstract

La presente se refiere a compuestos de fórmula (1) en la que: R¹ es CH₃, R¹ es metilo, etilo, CF₃, ciclopropilo, CH₂OH o R¹ y R¹ pueden formar conjuntamente con el átomo de carbono al que se encuentran unidos un anillo 1,1-dioxo-tiolán-3-ilo, R² es hidrógeno, metilo, etilo, isopropilo, terc-butilo, ciclopropilo, CH₂OH o C(CH₃)₂OH, R³ es Cl, F, CF₃, ciano, metilo o ciclopropilo, R⁴ es hidrógeno, metilo o F, o a una sal o sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica o a su enantiómero y/o isómero óptico y/o estereoisómero correspondiente de los mismos, para la utilización en el tratamiento de trastornos psiquiátricos tales como la esquizofrenia, el trastorno bipolar, el trastorno obsesivo-compulsivo o trastornos del espectro autista.
ARP160101615A 2015-06-04 2016-06-02 Derivados imidazol AR104863A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15170671 2015-06-04

Publications (1)

Publication Number Publication Date
AR104863A1 true AR104863A1 (es) 2017-08-23

Family

ID=53284112

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101615A AR104863A1 (es) 2015-06-04 2016-06-02 Derivados imidazol

Country Status (8)

Country Link
US (1) US10029989B2 (es)
EP (1) EP3303299B1 (es)
JP (1) JP6877359B2 (es)
CN (1) CN107531642B (es)
AR (1) AR104863A1 (es)
HK (1) HK1245269A1 (es)
TW (1) TW201718511A (es)
WO (1) WO2016193235A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207449B (zh) 2015-04-23 2020-11-10 豪夫迈·罗氏有限公司 用于治疗精神障碍的四唑衍生物
JP6831376B2 (ja) 2015-10-06 2021-02-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ トリアゾール誘導体
CN108473462B (zh) 2016-02-02 2021-06-22 豪夫迈·罗氏有限公司 作为eaat3抑制剂的吡唑-吡啶衍生物
WO2017202896A1 (en) * 2016-05-27 2017-11-30 F. Hoffmann-La Roche Ag Pyrazol compounds as eaat3 inhibitors
WO2018069362A1 (en) 2016-10-14 2018-04-19 F. Hoffmann-La Roche Ag Imidazole compounds as eaat3 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939556B2 (en) * 2005-10-14 2011-05-10 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
EP2038264B1 (en) * 2006-06-29 2016-10-26 F.Hoffmann-La Roche Ag Tetrazole-substituted arylamides
CA2703909A1 (en) * 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
WO2009077365A1 (en) * 2007-12-17 2009-06-25 F. Hoffmann-La Roche Ag Novel imidazole-substituted arylamides
CN107207449B (zh) * 2015-04-23 2020-11-10 豪夫迈·罗氏有限公司 用于治疗精神障碍的四唑衍生物

Also Published As

Publication number Publication date
HK1245269A1 (zh) 2018-08-24
EP3303299A1 (en) 2018-04-11
EP3303299B1 (en) 2019-04-24
JP6877359B2 (ja) 2021-05-26
US10029989B2 (en) 2018-07-24
WO2016193235A1 (en) 2016-12-08
CN107531642B (zh) 2021-06-22
TW201718511A (zh) 2017-06-01
US20180118692A1 (en) 2018-05-03
JP2018516873A (ja) 2018-06-28
CN107531642A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
CL2018000036A1 (es) Derivados etinilo
AR104863A1 (es) Derivados imidazol
AR105662A1 (es) Derivados de piridina y de pirimidina como inhibidores del eaat3
AR104331A1 (es) Derivados de tetrazol
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
AR099047A1 (es) Derivados etinilo
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR096640A1 (es) Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
GT201300207A (es) Derivados de heteroarilo como moduladores de nachr alfa 7
AR098522A1 (es) Compuesto de triazolo-piridina
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
AR097721A1 (es) Derivados de etinilo
AR105327A1 (es) Derivados de imidazol
AR093042A1 (es) Derivados de etinilo
AR107490A1 (es) Derivados de pirazol-piridina como inhibidores de eaat3
CO2018013824A2 (es) Derivados de etinilo
AR099529A1 (es) Derivados de etinilo, un proceso para su fabricación; composiciones farmacéuticas que los comprenden y su uso en el tratamiento de enfermedades del sistema nervioso o cáncer
AR106475A1 (es) Derivados de piridina o de pirimidina
AR103952A1 (es) Derivados de pirimidina-diona
EA201692404A1 (ru) Пептиды, выполняющие роль агонистов окситоцина
AR099300A1 (es) Hexahidrofuropirroles como inhibidores de pde1
CR20150143A (es) Derivados de etinilo como moduladores del receptor de actividad mglur5
AR092097A1 (es) Derivados de ariletinilo

Legal Events

Date Code Title Description
FB Suspension of granting procedure